Skip to content

EBITDA at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.39M-45.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$59.81M+21.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$83.58M-35.1%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

$98.4Mebit+
$871.0KDepreciation Depletion & Amortization
=-$97.54M

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s EBITDA?
Alumis Inc. (ALMS) reported EBITDA of -$97.54M in Q1 2026.
How has Alumis Inc.'s EBITDA changed year-over-year?
Alumis Inc.'s EBITDA increased by 3.1% year-over-year, from -$100.69M to -$97.54M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.